UnitedHealth Group Faces US Justice Department Investigation for Possible Medicare Fraud

The US Justice Department is investigating UnitedHealth Group for possible Medicare fraud in its Medicare Advantage program, a report by the Wall Street Journal claimed. This probe marks the latest challenge for the largest health insurer in the US, following last week's unexpected departure of its CEO and a high-profile case of corporate sabotage. The investigation focuses on allegations that the company directed doctors to make patient diagnoses that would trigger high government payments under Medicare Advantage. UnitedHealth has denied any wrongdoing and criticized the news article, stating it had not been notified of the investigation.

Key Takeaways:

• The US Justice Department is investigating UnitedHealth Group for possible Medicare fraud in its Medicare Advantage program, according to a report by the Wall Street Journal.
• The investigation revolves around allegations that UnitedHealth directed doctors to make patient diagnoses that would trigger high government payments under Medicare Advantage.
• This probe comes after the company's CEO unexpectedly announced his departure due to personal reasons and the company suspended its 2025 outlook citing higher-than-expected costs.
• UnitedHealth Group shares have seen significant declines in pre-market trading, dropping 6.6% to USD287.80, with a market capitalization of USD279.41 billion.
• The company has denied wrongdoing, criticizing the news article and stating it had not been notified of the investigation.
• The case brings to the surface deep public frustration with the lucrative US commercial healthcare system, as exemplified by the high-profile case of Brian Thompson, the head of UnitedHealth's insurance division, who was killed last December.
• UnitedHealth has previously faced investigation over alleged Medicare Advantage scheme, with the Wall Street Journal reporting in February that it was under investigation over allegations of directing doctors to make patient diagnoses for high government payments.

Statistics:

• UnitedHealth Group's shares dropped 6.6% in pre-market trading, reaching USD287.80.
• The company faces a market capitalization of USD279.41 billion.
• The unexpectedly announced departure of the CEO caused a 12% drop in shares on Tuesday.
• The company has suspended its 2025 outlook due to higher-than-expected costs.
• The alleged Medicare Advantage scheme involved directing doctors to make patient diagnoses for high government payments.

Sources:

• AFP (Associated Press)
• Wall Street Journal (Original source of the investigation report)